바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev
e-Submission

Vol.73 No.4
Citation Share

A Case of Peritoneal Tuberculosis Developed after Infliximab Therapy for Refractory RA

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2012, v.73 no.4, pp.234-238
https://doi.org/10.4046/trd.2012.73.4.234
Ji-Yeon Min (Hanyang University Guri Hospital)
Tae-Hyung Kim (Hanyang University Guri Hospital)
(Hanyang University Guri Hospital)
Seung-Yeon Min (Hanyang University Guri Hospital)
Dae-Sung Lee (Hanyang University Guri Hospital)
Bo-Sang Kim (Hanyang University Guri Hospital)
Jeong-Eun Kim (Hanyang University Guri Hospital)
Eun-Sung Lee (Hanyang University Guri Hospital)
Ju Yeon Pyo (Hanyang University Guri Hospital)
Jang-Won Sohn (Hanyang University College of Medicine)
(Hanyang University Guri Hospital)
Ji-Yeon, M. , Tae-Hyung, K. , Seung-Yeon, M. , Dae-Sung, L. , Bo-Sang, K. , Jeong-Eun, K. , Eun-Sung, L. , Ju, Y. P. , Jang-Won, S. , & (2012). A Case of Peritoneal Tuberculosis Developed after Infliximab Therapy for Refractory RA. Tuberculosis & Respiratory Diseases, 73(4), 234-238, https://doi.org/10.4046/trd.2012.73.4.234
  • Downloaded
  • Viewed
PDF Download

Abstract

Recently, interferon gamma releasing assay has been recommended to compensate the tuberculin skin test (TST) for screening for latent tuberculosis infection (LTBI). Although it improved the detection of LTBI before treatment with tumor necrosis factor blocker, its application to immune suppressed patients is limited. We report a case of peritoneal tuberculosis (TB) developed in a patient who tested positive for TST and QuantiFERON-TB Gold (QFT-G) before infliximab therapy, to emphasize the importance of monitoring during treatment. A 52-year-old woman presented with abdominal distension. She had been diagnosed with seropositive rheumatoid arthritis six years ago. She had started taking infliximab six months ago. All screening tests for TB were performed and the results of all were negative. At admission, the results of repeated TST and QFT-G tests were positive. Histopathological examination confirmed peritoneal TB. The patient started anti-TB therapy and the symptoms were relieved.

keywords
Peritonitis, Tuberculous, Infliximab

Reference

1.

1. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011;50: 196-203.

2.

2. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.

3.

3. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.

4.

4. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34: 706-11.

5.

5. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001;345:1098- 104.

6.

6. Kwok SK, Park SH. Guidelines for prevention of tuberculosis in patients with rheumatoid arthritis treated with TNF-alpha blockers. J Korean Rheum Assoc 2007; 14:105-11.

7.

7. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.

8.

8. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293: 2756-61.

9.

9. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-67.

10.

10. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64: 1360-1.

11.

11. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81.

12.

12. Park H, Park CW, Kim KB, Lee MJ, Zeon SJ, Shim SC, et al. A case of peritoneal tuberculosis with Poncet's disease in a patient treated with infliximab. J Rheum Dis 2011;18:55-9.

13.

13. Kim IT, Park HB, Lee SH, Hyun YK, Kim YJ, Lee YW, et al. Tuberculous peritonitis in a patient with rheumatoid arthritis treated with infliximab. J Rheum Dis 2011;18:320-3.

14.

14. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy